83 results
424B5
NMTC
NeuroOne Medical Technologies Corporation
16 Aug 24
Prospectus supplement for primary offering
4:30pm
for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological … such as Parkinson’s disease, essential tremor, dystonia, and chronic pain. Alzheimer’s is another indication evaluating the effects of DBS. Unlike ablative
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corporation
14 Aug 24
NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce
8-K
EX-99.1
vcxa6e2q7lovy2
14 May 24
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:10pm
8-K
EX-99.1
2izuf 1dkn6j3h
26 Mar 24
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
9:20am
8-K
EX-99.1
42wlha4aunw8mfanf
15 Mar 24
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
EX-99.1
dvg 1qpps
13 Feb 24
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
r5omv
14 Dec 23
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.1
g0p2pwmgpvrkc0t5vp
11 Dec 23
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
8:15am
8-K
EX-99.1
85io60s
16 Nov 23
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
8:00am
8-K
EX-99.1
6p2s3o
14 Nov 23
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
5:28pm
8-K
EX-99.1
eod7cvewz
7 Nov 23
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
8:15am